|
1
|
Bade BC and Dela Cruz CS: Lung cancer
2020: Epidemiology, etiology, and prevention. Clin Chest Med.
41:1–24. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arriagada R, Bergman B, Dunant A, Le
Chevalier T, Pignon JP and Vansteenkiste J; International Adjuvant
Lung Cancer Trial Collaborative Group, : Cisplatin-based adjuvant
chemotherapy in patients with completely resected non-small-cell
lung cancer. N Engl J Med. 350:351–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Douillard JY, Tribodet H, Aubert D,
Shepherd FA, Rosell R, Ding K, Veillard AS, Seymour L, Le Chevalier
T, Spiro S, et al: Adjuvant cisplatin and vinorelbine for
completely resected non-small cell lung cancer: Subgroup analysis
of the lung adjuvant cisplatin evaluation. J Thorac Oncol.
5:220–228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Asamura H, Goya T, Koshiishi Y, Sohara Y,
Eguchi K, Mori M, Nakanishi Y, Tsuchiya R, Shimokata K, Inoue H, et
al: A Japanese lung cancer registry study: Prognosis of 13,010
resected lung cancers. J Thorac Oncol. 3:46–52. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nadkar A, Pungaliya C, Drake K, Zajac E,
Singhal SS and Awasthi S: Therapeutic resistance in lung cancer.
Expert Opin Drug Metab Toxicol. 2:753–777. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gottesman MM: Mechanisms of cancer drug
resistance. Annu Rev Med. 53:615–627. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gottesman MM and Ling V: The molecular
basis of multidrug resistance in cancer: The early years of
P-glycoprotein research. FEBS Lett. 580:998–1009. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sadeghi MR, Jeddi F, Soozangar N, Somi MH,
Shirmohamadi M, Khaze V and Samadi N: Nrf2/P-glycoprotein axis is
associated with clinicopathological characteristics in colorectal
cancer. Biomed Pharmacother. 104:458–464. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nakanishi T, Menju T, Nishikawa S,
Takahashi K, Miyata R, Shikuma K, Sowa T, Imamura N, Hamaji M,
Motoyama H, et al: The synergistic role of ATP-dependent drug
efflux pump and focal adhesion signaling pathways in vinorelbine
resistance in lung cancer. Cancer Med. 7:408–419. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang S, Qi Q, Chan CB, Zhou W, Chen J,
Luo HR, Appin C, Brat DJ and Ye K: Fyn-phosphorylated PIKE-A binds
and inhibits AMPK signaling, blocking its tumor suppressive
activity. Cell Death Differ. 23:52–63. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singh MM, Howard A, Irwin ME, Gao Y, Lu X,
Multani A and Chandra J: Expression and activity of Fyn mediate
proliferation and blastic features of chronic myelogenous leukemia.
PLOS One. 7:e516112012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Posadas EM, Al-Ahmadie H, Robinson VL,
Jagadeeswaran R, Otto K, Kasza KE, Tretiakov M, Siddiqui J, Pienta
KJ, Stadler WM, et al: FYN is overexpressed in human prostate
cancer. BJU Int. 103:171–177. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Elias D, Vever H, Lænkholm AV, Gjerstorff
MF, Yde CW, Lykkesfeldt AE and Ditzel HJ: Gene expression profiling
identifies FYN as an important molecule in tamoxifen resistance and
a predictor of early recurrence in patients treated with endocrine
therapy. Oncogene. 34:1919–1927. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chiu WH, Luo SJ, Chen CL, Cheng JH, Hsieh
CY, Wang CY, Huang WC, Su WC and Lin CF: Vinca alkaloids cause
aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA
damage, mitochondrial dysfunction, and apoptosis in lung
adenocarcinoma cells. Biochem Pharmacol. 83:1159–1171. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xue D, Zhou X and Qiu J: Emerging role of
NRF2 in ROS-mediated tumor chemoresistance. Biomed Pharmacother.
131:1106762020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ren D, Villeneuve NF, Jiang T, Wu T, Lau
A, Toppin HA and Zhang DD: Brusatol enhances the efficacy of
chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Proc Natl Acad Sci USA. 108:1433–1438. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoshino H, Murakami K, Nawamaki M and
Kashiwakura I: Effects of Nrf2 knockdown on the properties of
irradiated cell conditioned medium from A549 human lung cancer
cells. Biomed Rep. 8:461–465. 2018.PubMed/NCBI
|
|
18
|
Shin BY, Jin SH, Cho IJ and Ki SH:
Nrf2-ARE pathway regulates induction of Sestrin-2 expression. Free
Radic Biol Med. 53:834–841. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lau A, Villeneuve NF, Sun Z, Wong PK and
Zhang DD: Dual roles of Nrf2 in cancer. Pharmacol Res. 58:262–270.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh A, Misra V, Thimmulappa RK, Lee H,
Ames S, Hoque MO, Herman JG, Baylin SB, Sidransky D, Gabrielson E,
et al: Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung
cancer. PLoS Med. 3:e4202006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Feng SL, Luo HB, Cai L, Zhang J, Wang D,
Chen YJ, Zhan HX, Jiang ZH and Xie Y: Ginsenoside Rg5 overcomes
chemotherapeutic multidrug resistance mediated by ABCB1
transporter: In vitro and in vivo study. J Ginseng Res. 44:247–257.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Goldstraw P: New TNM classification:
Achievements and hurdles. Transl Lung Cancer Res. 2:264–272.
2013.PubMed/NCBI
|
|
23
|
Huang Z, Ouyang M, Lu S, Wang Y and Peng
Q: Optogenetic control for investigating subcellular localization
of Fyn kinase activity in single live cells. J Mol Biol.
432:1901–1909. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Resh MD: Fyn, a Src family tyrosine
kinase. Int J Biochem Cell Biol. 30:1159–1162. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kitamura H and Motohashi H: NRF2 addiction
in cancer cells. Cancer Sci. 109:900–911. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh A, Boldin-Adamsky S, Thimmulappa RK,
Rath SK, Ashush H, Coulter J, Blackford A, Goodman SN, Bunz F,
Watson WH, et al: RNAi-mediated silencing of nuclear factor
erythroid-2-related factor 2 gene expression in non-small cell lung
cancer inhibits tumor growth and increases efficacy of
chemotherapy. Cancer Res. 68:7975–7984. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bryan HK, Olayanju A, Goldring CE and Park
BK: The Nrf2 cell defence pathway: Keap1-dependent and -independent
mechanisms of regulation. Biochem Pharmacol. 85:705–717. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Osburn WO and Kensler TW: Nrf2 signaling:
An adaptive response pathway for protection against environmental
toxic insults. Mutat Res. 659:31–39. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jaiswal AK: Nrf2 signaling in coordinated
activation of antioxidant gene expression. Free Radic Biol Med.
36:1199–1207. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hayashi A, Suzuki H, Itoh K, Yamamoto M
and Sugiyama Y: Transcription factor Nrf2 is required for the
constitutive and inducible expression of multidrug
resistance-associated protein 1 in mouse embryo fibroblasts.
Biochem Biophys Res Commun. 310:824–829. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Vollrath V, Wielandt AM, Iruretagoyena M
and Chianale J: Role of Nrf2 in the regulation of the MRP2 (ABCC2)
gene. Biochem J. 395:599–609. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Homma S, Ishii Y, Morishima Y, Yamadori T,
Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N,
et al: Nrf2 enhances cell proliferation and resistance to
anticancer drugs in human lung cancer. Clin Cancer Res.
15:3423–3432. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tarumoto T, Nagai T, Ohmine K, Miyoshi T,
Nakamura M, Kondo T, Mitsugi K, Nakano S, Muroi K, Komatsu N and
Ozawa K: Ascorbic acid restores sensitivity to imatinib via
suppression of Nrf2-dependent gene expression in the
imatinib-resistant cell line. Exp Hematol. 32:375–381. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang XJ, Li Y, Luo L, Wang H, Chi Z, Xin
A, Li X, Wu J and Tang X: Oxaliplatin activates the Keap1/Nrf2
antioxidant system conferring protection against the cytotoxicity
of anticancer drugs. Free Radic Biol Med. 70:68–77. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kim SK, Yang JW, Kim MR, Roh SH, Kim HG,
Lee KY, Jeong HG and Kang KW: Increased expression of
Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant
breast cancer cells. Free Radic Biol Med. 45:537–546. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Hu Q, Qin Y, Xiang J, Liu W, Xu W, Sun Q,
Ji S, Liu J, Zhang Z, Ni Q, et al: dCK negatively regulates the
NRF2/Are axis and ROS production in pancreatic cancer. Cell Prolif.
51:e124562018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shibata T, Kokubu A, Gotoh M, Ojima H,
Ohta T, Yamamoto M and Hirohashi S: Genetic alteration of Keap1
confers constitutive Nrf2 activation and resistance to chemotherapy
in gallbladder cancer. Gastroenterology. 135:1358–1368.
1368.e1351–e1354. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arias-Salgado EG, Lizano S, Sarkar S,
Brugge JS, Ginsberg MH and Shattil SJ: Src kinase activation by
direct interaction with the integrin beta cytoplasmic domain. Proc
Natl Acad Sci USA. 100:13298–13302. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Reddy KB, Smith DM and Plow EF: Analysis
of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling.
J Cell Sci. 121:1641–1648. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cooper J and Giancotti FG: Integrin
signaling in cancer: Mechanotransduction, stemness, epithelial
plasticity, and therapeutic resistance. Cancer Cell. 35:347–367.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Campbell EJ, McDuff E, Tatarov O, Tovey S,
Brunton V, Cooke TG and Edwards J: Phosphorylated c-Src in the
nucleus is associated with improved patient outcome in ER-positive
breast cancer. Br J Cancer. 99:1769–1774. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kaplan KB, Swedlow JR, Varmus HE and
Morgan DO: Association of p60c-src with endosomal membranes in
mammalian fibroblasts. J Cell Biol. 118:321–333. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sandilands E, Cans C, Fincham VJ, Brunton
VG, Mellor H, Prendergast GC, Norman JC, Superti-Furga G and Frame
MC: RhoB and actin polymerization coordinate Src activation with
endosome-mediated delivery to the membrane. Dev Cell. 7:855–869.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nishikawa S, Menju T, Takahashi K, Miyata
R, Sonobe M, Yoshizawa A and Date H: Prognostic significance of
phosphorylated Fyn in patients with lung adenocarcinoma after lung
resection. Ann Thorac Cardiovasc Surg. 25:246–252. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wakabayashi N, Itoh K, Wakabayashi J,
Motohashi H, Noda S, Takahashi S, Imakado S, Kotsuji T, Otsuka F,
Roop DR, et al: Keap1-null mutation leads to postnatal lethality
due to constitutive Nrf2 activation. Nat Genet. 35:238–245. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kang MI, Kobayashi A, Wakabayashi N, Kim
SG and Yamamoto M: Scaffolding of Keap1 to the actin cytoskeleton
controls the function of Nrf2 as key regulator of cytoprotective
phase 2 genes. Proc Natl Acad Sci USA. 101:2046–2051. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kaspar JW and Jaiswal AK: Tyrosine
phosphorylation controls nuclear export of Fyn, allowing Nrf2
activation of cytoprotective gene expression. FASEB J.
25:1076–1087. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jain AK and Jaiswal AK: GSK-3beta acts
upstream of Fyn kinase in regulation of nuclear export and
degradation of NF-E2 related factor 2. J Biol Chem.
282:16502–16510. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Tokunaga Y, Hosogi H, Hoppou T, Nakagami
M, Tokuka A and Ohsumi K: Effects of MDR1/P-glycoprotein expression
on prognosis in advanced colorectal cancer after surgery. Oncol
Rep. 8:815–819. 2001.PubMed/NCBI
|
|
50
|
Li W and Song M: Expression of multidrug
resistance proteins in invasive ductal carcinoma of the breast.
Oncol Lett. 8:2103–2109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Park SH, Park CJ, Kim DY, Lee BR, Kim YJ,
Cho YU and Jang S: MRP1 and P-glycoprotein expression assays would
be useful in the additional detection of treatment non-responders
in CML patients without ABL1 mutation. Leuk Res. 39:1109–1116.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kawasaki Y, Ishigami S, Arigami T,
Uenosono Y, Yanagita S, Uchikado Y, Kita Y, Nishizono Y, Okumura H,
Nakajo A, et al: Clinicopathological significance of nuclear factor
(erythroid-2)-related factor 2 (Nrf2) expression in gastric cancer.
BMC Cancer. 15:52015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang J, Jiao Q, Kong L and Yu J, Fang A,
Li M and Yu J: Nrf2 and Keap1 abnormalities in esophageal squamous
cell carcinoma and association with the effect of
chemoradiotherapy. Thorac Cancer. 9:726–735. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Solis LM, Behrens C, Dong W, Suraokar M,
Ozburn NC, Moran CA, Corvalan AH, Biswal S, Swisher SG, Bekele BN,
et al: Nrf2 and Keap1 abnormalities in non-small cell lung
carcinoma and association with clinicopathologic features. Clin
Cancer Res. 16:3743–3753. 2010. View Article : Google Scholar : PubMed/NCBI
|
